|
11 Apr 2022 |
BioNTech Presents Positive Preliminary Phase 1/2 Data for First-in-Class CAR-T Program BNT211 at AACR
|
|
11 Apr 2022 |
Orchard Therapeutics Announces Reimbursement Agreement Making Libmeldy Available for All Eligible MLD Patients in Italy
|
|
11 Apr 2022 |
PACT Reports New Data on First-of-its-Kind Personalized Neoantigen Platform for Adoptive T Cell Therapies at American Association for Cancer Research (AACR) Annual Meeting 2022
|
|
11 Apr 2022 |
Artiva Biotherapeutics Announces Agreement with Merck to Evaluate Combinations of NK Cells with Tri-Specific NK-Cell Engagers
|
|
11 Apr 2022 |
CytoImmune Presents New Preclinical Data Demonstrating Potential of its Novel, Off-the-Shelf Natural Killer Cell-Based Therapies for the Treatment of Hematologic and Solid Tumor Cancers at AACR
|
|
11 Apr 2022 |
Seneca Therapeutics, Inc. Presents Promising New Preclinical Data Combining its Lead Oncolytic Immunotherapeutic SVV-001 in Combination with Checkpoint Inhibitors at the 2022 Annual AACR Meeting
|
|
11 Apr 2022 |
MiNA Therapeutics Presents Proof of Mechanism Data on MTL-STING as a Novel Cancer Immunotherapy
|
|
10 Apr 2022 |
Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022
|
|
10 Apr 2022 |
Cellectis Presents Preclinical Data from its First Allogeneic Dual CAR T-cell Product Candidate UCART20x22 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma at the American Association for Cancer Research (AACR) 2022 Annual Meeting
|
|
10 Apr 2022 |
Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting
|
|
09 Apr 2022 |
Cytovia Therapeutics Reports Preclinical Activity of its iPSC-derived NK (iNK) Cells and Flex-NK™ Cell Engagers at the 2022 AACR Annual Meeting
|
|
09 Apr 2022 |
Catamaran Bio Presents Preclinical In Vivo Efficacy Data Supporting Advancement of CAT 179, a HER2-targeted Allogeneic CAR-NK Cell Therapy
|
|
09 Apr 2022 |
2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting
|
|
08 Apr 2022 |
T-knife Therapeutics Announces New TCR-T Program Targeting KRAS G12V and Presents Data at the American Association for Cancer Research (AACR) Annual Meeting
|
|
08 Apr 2022 |
Dystrogen Therapeutics Investigational Chimeric Cell Therapy DT-DEC01 for the Treatment of Duchene Muscular Dystrophy Shows Safety and Functional Improvements
|
|
07 Apr 2022 |
Pregene Enters into Innovative Partnership with CellPoint to Develop anti-BCMA CAR-T Cell Therapy in Europe and the US
|
|
07 Apr 2022 |
Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma
|
|
05 Apr 2022 |
AZD8233 reduced low-density lipoprotein cholesterol levels by 73% in patients with high-risk hypercholesterolemia in ETESIAN Phase IIb trial
|
|
04 Apr 2022 |
Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session
|
|
02 Apr 2022 |
Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)
|
|
01 Apr 2022 |
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
|
|
01 Apr 2022 |
Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center
|
|
01 Apr 2022 |
JW Therapeutics Announces IND Approval for the Pivotal Clinical Trial of Carteyva® in Second-line Large B-Cell Lymphoma
|
|
01 Apr 2022 |
TILT Biotherapeutics Announces Positive Update on its Phase 1 Immunotherapy Clinical Trials in Cancer
|
|
30 Mar 2022 |
Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome
|
